Skip to main content

Defining What is Value-Based Care for Patients with ​Relapsed/Refractory Chronic Lymphocytic Leukemia​

By July 6, 2018July 31st, 2018No Comments
Evidence-Based Clinical Updates in the Treatment of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia - G411

Defining What is Value-Based Care for Patients with ​Relapsed/Refractory Chronic Lymphocytic Leukemia​​

Release Date: July 6, 2018
Expiration Date:
July 6, 2019


150 minutes (2.5 hours)​

Download Slides (PPT)    Take Post-test


The target audiences for these activities are hematologists, medical oncologists, pulmonologists, pathologists, physician assistants, nurse practitioners, registered nurses, oncology nurses, nurse navigators, palliative/symptom management teams who care for patients with chronic lymphocytic leukemia (​​CLL) and quality administrators responsible for their cancer center’s adherence to value-based care delivery models.


At the conclusion of these educational initiatives, participants should be able to:

  • Assess the implications of CMS value-based care initiatives on community and academic oncology practices​
  • Practice evidence-based guidelines to treat patients with relapsed/refractory CLL​
  • Employ a risk assessment model in clinical workflow to support treatment and surveillance planning for patients with relapsed/refractory CLL​
  • Incorporate data on the safety profiles of current and emerging therapies for the treatment of CLL to monitor and manage adverse events ​
  • Implement effective patient education strategies regarding disease, treatment, and side-effect management


​In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Carevive Systems, Inc. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


The Postgraduate Institute for Medicine designates this enduring material for a maximum of 2.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


The maximum number of hours awarded for this Continuing Nursing Education activity is 2.50 contact hours. Designated for 0.8 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.


Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.​

​Faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Faculty Disclosures:

  • Amit Mehta, MDConsulting Fees, BMS, Kite; Other, Gilead.​
  • Ashley Leak Bryant PhD, RN-BC, OCNhas no real or apparent conflicts of interest to report.​
  • Amy Goodrich, MSN, RN, CRNP-ACConsulting Fees, Gilead.​
  • Alberto Montero, MD, MBA, CPHQConsulting Fees, Carevive Systems, Inc.​


The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:​

The PIM planners and managers have nothing to disclose. Carevive planners/managers and patient have no conflicts of interest to report.​


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  ​

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.​


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.​


There are no fees for participating and receiving CME/CE credit for this activity. During the period 07/06/2018 through 07/05/2019, participants must read the learning objectives and faculty disclosures and study the educational activity.​​  If you wish to receive acknowledgment for completing this activity, please complete the post-test and evaluation on  On the navigation menu, click on “Find Post-test/Evaluation by Course” and search by course ID 13644.

Please contact the Postgraduate Institute for Medicine (PIM) at www.Pimed.comwith any accreditation questions.


Online Power Point​

Download Slides (PPT)    Take Post-test

Postgraduate Institute for Medicine and Carevive Logos

Jointly provided by Postgraduate Institute for Medicine and Carevive Systems, Inc.​

​This activity is supported by an independent educational grant from Genentech BioOncology.​ Activity ID: G-420